Search results for "Oncoprotein"

showing 3 items of 3 documents

Bcl-2 as prognostic factor in head and neck squamous cell carcinoma

2005

A series of 66 cases of oral squamous cell carcinoma (OSCC) was retrospectively analyzed by immunohisto-chemistry for bcl-2 expression to verify its predictive value for clinical outcome in patients with OSCC. After grouping for bcl-2 expression, OSCCs were statistically analyzed for the variables age, gender, histological grading (G), TNM, staging, recurrence, and overall survival rate. Univariate and multivariate (Cox regression) analyses were performed. Thirty-six OSCC (54.5%) showed expression for bcl-2, whereas 30 (44.5%) were negative. No statistical association was found between bcl-2 expression and any variables considered at baseline. Overall disease-specific survival rate at 72 mo…

AdultMaleEXPRESSIONOncologyCancer Researchmedicine.medical_specialtyPathologyAdolescentSPONTANEOUS APOPTOSISPROTEINBCL-2Internal medicinemedicineCarcinomaHumansPROGNOSTIC SIGNIFICANCEGrading (tumors)Survival rateIMMUNOHISTOCHEMICAL ANALYSISORAL-CAVITYIN-VIVOAgedRetrospective StudiesAged 80 and overProportional hazards modelbusiness.industryCancerRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseImmunohistochemistryCANCERHead and neck squamous-cell carcinomaSurvival RateFAMILY-MEMBERSstomatognathic diseasesProto-Oncogene Proteins c-bcl-2OncologySQUAMOUS CELL CARCINOMAHead and Neck NeoplasmsBAXCarcinoma Squamous CellRegression AnalysisImmunohistochemistryFemalebusinessONCOPROTEIN
researchProduct

Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia

2017

Abstract Ethnopharmacological relevance Ancient mediterranean diet was characterized by consuming the spontaneous forms of Cynara cardunculus L. (CCL), commonly called artichoke. Cultivated and/or spontaneous forms of CC studies have demonstrated that methanol extract of CCL flower and/or cynaropicrin showed remarkable anti-proliferative activity in vitro models of leukocyte cancer cell. Aim of the study Chronic myeloid leukemia (CML) is associated with a reciprocal translocation of the long arms of chromosomes 9 and 22 generating the BCR/ABL fusion gene, translated in the p210 BCR/ABL oncoprotein kinase. This chimeric protein is the target of a kinase inhibitor, imatinib, but the developme…

Cynara cardunculus L.Sesquiterpene0301 basic medicineSettore MED/06 - Oncologia MedicaFusion Proteins bcr-ablPharmacologyAntineoplastic AgentLactoneschemistry.chemical_compound0302 clinical medicinehemic and lymphatic diseasesDrug DiscoveryK562 cellABLChemistryChronic myeloid leukemiabreakpoint cluster regionMyeloid leukemiaLactoneCynaropicrinImatinib resistantChemotherapy Adjuvant030220 oncology & carcinogenesisImatinib MesylateChronic myeloid leukemia; Cynara cardunculus L.; Imatinib resistant; K562 cells; P210BCR/ABLoncoprotein; Antineoplastic Agents; Antineoplastic Agents Phytogenic; Cell Survival; Chemotherapy Adjuvant; Cynara; Drug Resistance Neoplasm; Fusion Proteins bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Lactones; Leukemia Myelogenous Chronic BCR-ABL Positive; Plant Extracts; Sesquiterpenes; Pharmacology; Drug Discovery3003 Pharmaceutical ScienceSesquiterpenesHumanmedicine.drugCell SurvivalAntineoplastic AgentsCynaraPlant Extract03 medical and health sciencesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansViability assayneoplasmsPharmacologyPlant ExtractsCell growthDrug Discovery3003 Pharmaceutical ScienceImatinibAntineoplastic Agents PhytogenicP210BCR/ABLoncoprotein030104 developmental biologyDrug Resistance NeoplasmCancer researchK562 CellsK562 cellsJournal of Ethnopharmacology
researchProduct

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/Wo…

2010

The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy for mCRC treatment. The meeting was conducted during the 11th ESMO/World Gastrointestinal Cancer Congress (WGICC) in Barcelona in June 2009. The manuscript describes the outcome of an expert discussion leading to an expert recommendation. The increasing knowledge on clinical and molecular markers and the availability of biological targeted therapies have major implications in the optimal management in mCRC. 21 Suppl 6 vi1 10

OncologyColorectal cancermedicine.medical_treatmentBraf proteinGastroenterologyMetastasisDrug antagonismTargeted therapyMetastasisAntineoplastic agentsPathologyConference paperBiological markersPredictive markerHematologyPrognosisChemotherapy regimenAntineoplastic agentOncologyProto-oncogene proteinsRas proteinHumanReceptormedicine.medical_specialtyNeoplasm metastasisRas proteinsMEDLINEOncoproteinColorectal neoplasmsProto-oncogene proteins b-rafInternal medicineGeneticsmedicineHumansGastrointestinal cancerColorectal tumorB raf kinaseEpidermal growth factor receptorKras proteinbusiness.industryEpidermal growth factorCancermedicine.diseasedigestive system diseasesBiological markerMetabolismSpainMutationCarcinoembryonic antigenMicrosatellite instabilitybusinessAnnals of Oncology
researchProduct